Fentiman I S, Balkwill F R, Cuzick J, Hayward J L, Rubens R D
ICRF Clinical Oncology Unit, Guy's Hospital, London, UK.
Eur J Surg Oncol. 1987 Oct;13(5):425-8.
Thirty-two women who had developed loco-regional recurrence of breast carcinoma were entered into a controlled trial of adjuvant alpha-interferon. All patients had histological confirmation of recurrence, local treatment with radiotherapy and negative staging investigations. They were then randomized to either observation alone, or treatment with human alpha interferon 3 x 10(6) units subcutaneously daily for 1 year. There were no differences detected in the rate of local or distant relapse. With this lack of clinically significant efficacy and a high incidence of side effects, it is concluded that alpha interferon is of doubtful value in the adjuvant treatment of breast cancer.
32例发生乳腺癌局部区域复发的女性患者进入了一项辅助性α-干扰素对照试验。所有患者均经组织学确诊复发，接受了放射治疗及阴性分期检查。然后将她们随机分为两组，一组仅接受观察，另一组每天皮下注射3×10⁶单位的人α干扰素，共治疗1年。结果发现局部或远处复发率并无差异。鉴于缺乏具有临床意义的疗效且副作用发生率高，得出的结论是α干扰素在乳腺癌辅助治疗中的价值存疑。
